品质为先。

     

APAC MARKETS

我们设法促进高度专业化和具有科学价值的领域的发展,以提高医疗保健的标准。

发现更多关于美纳里尼集团的信息

30 多年来,美纳里尼一直致力于推动研发,为受严重健康问题影响的患者提供创新且有效的药物和医疗保健解决方案。

在13个主要市场获取进入亚太地区所有主要市场的单点式入口。

分享您的合作意向

充分利用我们的全渠道方法使您的品牌在亚太地区增长。

MARKETS

亚太地区的医疗行业正在快速增长。美纳里尼亚太隶属于世界领先的意大利生物制药公司,在该地区13个主要市场拥有强大的布局。

作为众多全球医疗保健公司的首选合作伙伴,我们参与整个药品开发生命周期,挖掘增长机会并扩大其品牌影响力。在此过程中,我们还为医务工作者和患者提供优质医疗产品和技术支持,以提高标准并为未来缔造健康生活。

我们的亚太地区总部

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

新闻

2017 - 03 - 12

Menarini arrives in Columbia and Peru

- TWO NEW AFFILIATES FOR A STRONGER CONNECTION BETWEEN TWO CONTINENTS –

The Menarini Group has consolidated its presence in Latin America with new affiliates in Colombia and Peru. Both countries have emerging economies which offer the company opportunities for market expansion with its high-quality pharmaceuticals. Two new affiliates have just been opened in Bogotá and Lima, strengthening the connection between two continents and creating a springboard for other areas of expansion in Latin America.

"We are enthusiastic about increasing our presence in Latin America with the opening of our branches in Peru and Colombia, strategic countries where Menarini has decided to strengthen its commitment to guarantee that patients have access to extremely high-quality medicinal products manufactured at our 15 Menarini sites", explained Alberto Giovanni Aleotti, Vice Chairman of the Menarini Group. This, he added, "represents a stepping stone for international growth of the Group, which is currently present in over 130 countries, with its presence in the USA being a particularly notable success."

The Menarini Group has a global annual turnover of € 3.46 billion. 

2017 opens with a new challenge for the Italian company which is specialised in medicinal products for pain relief and cardiovascular, respiratory, digestive tract and urological treatment. The company is also committed to research and development into new cancer treatments.

Colombia, a country with a population of over 47 million, is among the top 20 countries in the world in terms of the amount of direct foreign investment it receives, according to the United Nations Conference on Trade and Development (UNCTAD). On 9 March, Menarini inaugurated its new office in the country's capital, Bogotá, where 40 people are now employed, including medical-scientific and administrative personnel. The inauguration event, held at the Italian Embassy, was attended by government officials, representatives from scientific companies and institutions, and medical staff. 

On 7 March, with an event held at the Lima Art Museum, the ribbon-cutting ceremony for Menarini in Peru was celebrated, which currently has 30 employees.

The first Menarini branch in Latin America was opened 38 years ago in Guatemala, with offices opening subsequently in El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and Belize. In these Central American countries and in the Caribbean, Menarini recorded an increase of 11% in the turnover for 2015, equal to € 93 million for the year. The Italian company has also had a direct presence in Mexico since 2009, and through its distributors it also makes its medicinal products available to the medical community in the Dominican Republic, Ecuador, Brazil, Argentina and Chile, offering work to almost 600 employees and in constant growth.

If you'd like to know more about Menarini, feel free to download our PDF files here.